Send As SMS

Wednesday, July 19, 2006

Ceragenix Pharmaceuticals - Colorado business, 5/2


Colorado business, 5/2
Denver Post - Ceragenix Pharmaceuticals Inc. , a Denver-based biopharmaceutical company, announced Monday that Steven Porter, its chairman and chief executive, will make a presentation at the Rodman & Renshaw third annual Global Healthcare Conference on May 15 in

Latest News
dBusinessNews.com - Ceragenix Obtains IRB Approval for Eczema Clinical Study; Study to Compare EpiCeram(R) to Mid-Strength Topical Steroid in Treatment of Children with Moderate-to-Severe Eczema DENVER -- Ceragenix Pharmaceuticals, Inc., a biopharmaceutical company

More trauma rooms permit family members' presence
KVOA 4 - NEW YORK, July 13 /PRNewswire-FirstCall/ -- On July 12, Steven Porter, CEO of Ceragenix Pharmaceuticals, Inc. updated the investment community in an exclusive interview with www.wallst.net . Topics covered in the interview include an overview of the

Innovations & ideas, 7/2
Denver Post - A Denver-based biotechnology company is looking at ways to treat eczema in children without using steroids. Ceragenix Pharmaceuticals Inc. said last week that it will begin a study of its topical cream Epiceram to see if it works just as well on

Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006
Genetic Engineering News - Ceragenix Ticker Symbol & Exchange: CGXP Investor Relations Contact: Robert Stanislaro Investor Relations Contact Phone: 212-850-5657 Web: www.ceragenix.com Date of Presentation: May 15 at 5:15